BIO-key International Receives Nasdaq Non-Compliance Notice Over Delayed 10-Q Filing
Holmdel, NJ, June 10, 2026 — BIO-key International, Inc. (“BIO-key” or the “Company”) has announced that it received a formal notice of non-compliance from The Nasdaq Stock Market, LLC (“Nasdaq”) related to the delayed filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The company disclosed this development in a Form 8-K filed with the U.S. Securities and Exchange Commission (“SEC”).
Key Points for Investors
- Non-Compliance Notice: On June 5, 2026, BIO-key received notification from Nasdaq’s Listing Qualifications Department that it was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires all listed companies to timely file their periodic financial reports with the SEC. The delay in filing the Form 10-Q for the quarter ending March 31, 2026, constitutes an additional basis for the potential delisting of the Company’s common stock from the Nasdaq Capital Market.
- Potential Delisting: The Nasdaq Hearing Panel (“Panel”) will consider this additional basis for delisting, along with previous compliance concerns, in determining whether BIO-key’s shares will remain listed on Nasdaq.
- Appeal in Progress: BIO-key has requested an appeal of Nasdaq’s prior determination (dated May 6, 2026) to suspend trading in the Company’s common stock. A hearing with the Panel is scheduled for June 16, 2026.
- Ongoing Compliance Efforts: The Company is actively taking all reasonable measures to regain compliance with the Periodic Report Rule and maintain its Nasdaq listing. However, there can be no assurance that these efforts will be successful or that the Panel will grant the Company’s request for continued listing.
Matters That May Be Price Sensitive
- Increased Delisting Risk: The failure to timely file required financial reports and the resulting Nasdaq notice significantly raise the risk of delisting from the Nasdaq Capital Market. Such a development could negatively impact the liquidity and market value of BIO-key’s common stock.
- Trading Status: If the Panel does not rule in favor of BIO-key, the Company’s shares could be delisted and may only be traded on over-the-counter (OTC) markets, which generally offer less liquidity and visibility to investors.
- Company Response: While BIO-key has stated its intention to regain compliance, the outcome is uncertain. Investors should monitor the results of the June 16, 2026 hearing and any subsequent actions taken by the Company or Nasdaq.
Additional Details and Context
- The Company’s shares currently trade under the symbol BKYI on the Nasdaq Capital Market.
- The Company’s business address is 101 Crawfords Corner Road, Suite 4116, Holmdel, NJ 07733, and its phone number is (732) 359-1100.
- The Form 8-K filing and attached press release reaffirm that the information regarding the non-compliance notice is not considered “filed” for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into any Securities Act or Exchange Act filings unless specifically stated.
What Should Shareholders Do?
Shareholders should be aware of the heightened risk that BIO-key may be delisted from Nasdaq if it does not regain compliance by timely filing its outstanding quarterly report and successfully appealing to the Nasdaq Hearing Panel. Delisting could lead to reduced liquidity, potential downward pressure on the share price, and increased difficulty in trading the stock. Investors are urged to follow future disclosures closely, especially updates following the critical June 16, 2026 hearing.
Contact Information
- Investor Relations: William Jones, David Collins, Catalyst IR, [email protected], (212) 924-9800
- Further Information: Visit www.BIO-key.com
-
Social Media:
Facebook: BIOkeyInternational
LinkedIn: BIO-key International
X (Twitter): @BIOkeyIntl (Corporate), @BIO_keyIR (Investors)
StockTwits: BIO_keyIR
Disclaimer: The information presented above is based on public filings made by BIO-key International, Inc. with the U.S. Securities and Exchange Commission and is intended solely for informational purposes. It does not constitute investment advice or a recommendation to buy, sell, or hold securities. Shareholders and prospective investors should conduct their own due diligence and consult their financial advisors prior to making any investment decisions. The outcome of the Nasdaq hearing and the Company’s ability to regain compliance are subject to uncertainties that could materially impact the Company’s stock price.
